Alia Brown, MD
Dermatology · Snellville, GANPI 1679613871
Payments from drug & device makers
Across 759 payments — averaging $1104.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$713K
- Regeneron$47K
- E.r. Squibb & Sons, L.L.C.$38K
- Novartis$13K
- Johnson & Johnson$9K
- Janssen Research & Development, LLC$4K
- plus $15K from 30 others
What the payments were for
- Consulting fees$14,81946%
- Grants$700%
- Travel & lodging$1,0103%
- Food & beverage$15,99849%
- Education$4471%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 244 | $712,670 |
| Regeneron | 35 | $46,612 |
| E.r. Squibb & Sons, L.L.C. | 23 | $38,471 |
| Novartis | 89 | $12,607 |
| Johnson & Johnson | 37 | $8,669 |
| Janssen Research & Development, LLC | 3 | $4,371 |
| LEO Pharma Inc. | 37 | $2,534 |
| Incyte Corporation | 12 | $2,449 |
| LEO Pharma AS | 2 | $2,310 |
| Regeneron Healthcare Solutions, Inc. | 42 | $1,152 |
| Sanofi | 33 | $1,051 |
| Lilly USA, LLC | 44 | $839 |
| Galderma Laboratories, L.p. | 28 | $792 |
| Pfizer | 32 | $723 |
| Arcutis Biotherapeutics, Inc. | 10 | $572 |
| UCB, Inc. | 15 | $405 |
| Dermavant Sciences, Inc. | 7 | $296 |
| Merz North America, Inc. | 4 | $259 |
| Sun Pharmaceutical Industries Inc. | 11 | $245 |
| Amgen | 6 | $244 |
| Almirall LLC | 7 | $126 |
| Bristol Myers Squibb | 1 | $116 |
| Lumenis, Inc | 1 | $111 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 6 | $104 |
| Boehringer Ingelheim | 5 | $96 |
| Verrica Pharmaceuticals Inc. | 3 | $87 |
| VYNE Pharmaceuticals Inc. | 3 | $80 |
| Janssen Scientific Affairs, LLC | 3 | $72 |
| Mayne Pharma Commercial LLC | 5 | $61 |
| Biofrontera Inc. | 3 | $43 |
| Strata Skin Sciences, Inc. | 2 | $39 |
| Botanix SB Inc | 2 | $33 |
| DUSA Pharmaceuticals, Inc. | 1 | $24 |
| Dermira, Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Organon | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$838,322 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 26 | $106,236 |
| Dupixent SyringeDupilumab | 12 | $45,579 |
| OpzeluraRuxolitinib Phosphate | 20 | $39,705 |
| Clobetasol Propionate | 89 | $3,790 |
| Betamethasone Dipropionate | 73 | $3,189 |
| Fluorouracil | 28 | $2,047 |
| Ketoconazole | 95 | $1,613 |
| Tranexamic Acid | 33 | $1,498 |
| Dutasteride | 55 | $1,236 |
| Minoxidil | 71 | $1,184 |
| Doxycycline Hyclate | 54 | $920 |
| Mupirocin | 138 | $825 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 11 | $563 |
| Triamcinolone Acetonide | 66 | $516 |
| CiclopiroxCiclopirox Olamine | 21 | $467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $2,449 | $39,70520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 345 dermatology providers in Georgia.
Other dermatology in Snellville
- Jonathan WeissSnellville$2.4M
- Jessica MercerSnellville$183K
- Brittany DupreeSnellville$22K
- David CohenMacon$5.5M
- Jamie WeismanAtlanta$4.9M
- Tiffani HamiltonAlpharetta$3.3M
- Firas HougeirDouglasville$3.3M
- Mark KnautzPowder Springs$1.7M
- Gerald SlagelFayetteville$1.2M
- Zakiya RiceAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.